The Fiji Pneumococcal Project that has been funded by NIH has been designed to provide all the information necessary to facilitate the early introduction of infant pneumococcal immunization into Fiji, a small developing country in the Pacific. The project has evaluated the burden of pneumonia, otitis media and pneumococcal meningitis in Fijian infants. This information, along with the results of a new study of the outcome of pneumococcal meningitis that is included with this application, will be used to build the economic argument for pneumococcal immunization. The vaccine trial will evaluate the impact of one, two or three doses of pneumococcal conjugate vaccine in infancy followed by a dose of pneumococcal polysaccharide vaccine at six or nine months of age on pneumococcal immunity, nasopharyngeal carriage of pneumococci and responses to a small dose of pneumococcal polysaccharide at 15 months of age. The trial has been delayed due to lack of availability of Prevenar, and additional costs incurred by this delay and improvements that have been made in the study design are included in this application. The results of this trial will guide pneumococcal immunization in the developing world. Since this trial was funded, similar studies have been commissioned by WHO but neither have yet commenced. In preparation for a future effectiveness study, involving the whole of Fiji, using the regimen determined to be most appropriate based oh the current study, and evaluating both the direct effectiveness of immunization (on vaccine recipients), and the indirect effectiveness or herd immunity effect (on older children and adults), a study of the etiology and epidemiology of pneumonia in all age groups in Fiji is also proposed. The results of this study will form the basis of an effectiveness evaluation following the pilot introduction of pneumococcal immunization into Fiji in 3-5 years time. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI052337-06
Application #
7281244
Study Section
Special Emphasis Panel (ZRG1-HOP-N (90))
Program Officer
Khambaty, Farukh M
Project Start
2002-09-30
Project End
2008-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
6
Fiscal Year
2007
Total Cost
$515,692
Indirect Cost
Name
University of Melbourne
Department
Type
DUNS #
753575117
City
Melbourne
State
Country
Australia
Zip Code
3010
Licciardi, Paul V; Russell, Fiona M; Balloch, Anne et al. (2014) Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage. Vaccine 32:2321-7
Licciardi, Paul V; Balloch, Anne; Russell, Fiona M et al. (2012) Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol 129:794-800.e2
Russell, F M; Balloch, A; Licciardi, P V et al. (2011) Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months. Vaccine 29:4499-506
Russell, F M; Carapetis, J R; Burton, R L et al. (2011) Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 29:535-44
Russell, F M; Carapetis, J R; Balloch, A et al. (2010) Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine 28:3341-9
Russell, F M; Licciardi, P V; Balloch, A et al. (2010) Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 28:3086-94
Licciardi, P V; Balloch, A; Russell, F M et al. (2010) Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization. Vaccine 28:3793-800
Balloch, Anne; Licciardi, Paul V; Russell, Fiona M et al. (2010) Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J Allergy Clin Immunol 126:395-7
Russell, F M; Balloch, A; Tang, M L K et al. (2009) Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine 27:5685-91